Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments, but further commercial validation is pending. The internal pipeline, led by REC-4881 for FAP, potentially lags competitors (more data is required) and is unlikely to generate significant revenue before 2030.
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.
Recursion Pharmaceuticals Q2 Earnings Call Highlights
Recursion Pharmaceuticals NASDAQ: RXRX outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028.
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.41 per share a year ago.
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.97, representing a -2.62% change from its previous close.
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.01, denoting a +1.69% move from the preceding trading day.
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $2.89, denoting a -1.87% move from the preceding trading day.
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.
